SIH Partners’s Allogene Therapeutics ALLO Stock Holding History

SIH Partners’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,747	Closed	-$20.1K	–	172
2025 Q1	$20.1K	Buy	+13,747	New	+$25.9K	﹤0.01%	265

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SIH Partners's ALLO Position: Q2 2025 in Review

SIH Partners sold out of Allogene Therapeutics (ALLO) in Q2 2025, closing a stake of 13,747 shares — an estimated $20.1K sold.

SIH Partners first reported a position in ALLO in Q1 2025 and held it in 1 quarter. The position peaked at $20.1K in Q1 2025. 158 funds tracked by Wall St. Rank hold ALLO as of Q2 2025.

SIH Partners reported no remaining Allogene Therapeutics position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 13,747 Allogene Therapeutics shares in Q2 2025, an estimated $20.1K.
SIH Partners first reported a position in Allogene Therapeutics in Q1 2025 and held it in 1 quarter.
SIH Partners's Allogene Therapeutics position peaked at $20.1K in Q1 2025.
158 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.